How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pathological-gastric-hypersecretory-condition.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pathological Gastric Hypersecretory Condition — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pathological Gastric Hypersecretory Condition (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pathological Gastric Hypersecretory Condition, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nexium	esomeprazole	AstraZeneca	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Aciphex	rabeprazole	Waylis	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01
Prilosec	omeprazole	AstraZeneca (originally Astra AB)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19	1989-09-14
Aciphex	Aciphex	University of Utah		Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3
Omeprazol	Omeprazol	RenJi Hospital		ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19
Rabeprazol	Rabeprazol	Janssen-Cilag, S.A.		Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Pathological Gastric Hypersecretory Condition
AstraZeneca · 1 drug in Pathological Gastric Hypersecretory Condition
AstraZeneca (originally Astra AB) · 1 drug in Pathological Gastric Hypersecretory Condition
Janssen-Cilag, S.A. · 1 drug in Pathological Gastric Hypersecretory Condition
RenJi Hospital · 1 drug in Pathological Gastric Hypersecretory Condition
University of Utah · 1 drug in Pathological Gastric Hypersecretory Condition
Waylis · 1 drug in Pathological Gastric Hypersecretory Condition

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pathological Gastric Hypersecretory Condition:

Cite this brief

Drug Landscape (2026). Pathological Gastric Hypersecretory Condition — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pathological-gastric-hypersecretory-condition. Accessed 2026-06-10.

Pathological Gastric Hypersecretory Condition full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing